IQWiG rebuffs Lyxumia for Type II diabetes

Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) said Lyxumia lixisenatide from Sanofi (Euronext:SAN; NYSE:SNY) has "no additional

Read the full 198 word article

How to gain access

Continue reading with a
two-week free trial.